12:00 AM
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avastin bevacizumab: Additional Phase III data

Additional data from the U.S. Phase III CATT trial in 1,107 evaluable patients with neovascular AMD showed that intravitreal Avastin produced similar effects on visual acuity at 2 years to that of Lucentis ranibizumab when the drugs were administered on either a monthly schedule or on an as needed basis. Specifically, patients receiving monthly Avastin or monthly Lucentis gained a mean of 7.8 and 8.8 letters, respectively, on the ETDRS eye chart from baseline to 2 years, while patients receiving Avastin as needed or Lucentis as needed gained 5 and 6.7 letters, respectively (p=0.21). Mean gains in visual acuity were significantly greater for monthly treatment with either drug than for as needed treatment (p=0.046). Additionally, switching...

Read the full 569 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >